These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Wang L; Amphlett G; Blättler WA; Lambert JM; Zhang W Protein Sci; 2005 Sep; 14(9):2436-46. PubMed ID: 16081651 [TBL] [Abstract][Full Text] [Related]
46. Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates. Puthenveetil S; Musto S; Loganzo F; Tumey LN; O'Donnell CJ; Graziani E Bioconjug Chem; 2016 Apr; 27(4):1030-9. PubMed ID: 26942771 [TBL] [Abstract][Full Text] [Related]
47. Development of Fluorophore-Labeled Thailanstatin Antibody-Drug Conjugates for Cellular Trafficking Studies. Kulkarni C; Finley JE; Bessire AJ; Zhong X; Musto S; Graziani EI Bioconjug Chem; 2017 Apr; 28(4):1041-1047. PubMed ID: 28191936 [TBL] [Abstract][Full Text] [Related]
49. Impact of Payload Hydrophobicity on the Stability of Antibody-Drug Conjugates. Buecheler JW; Winzer M; Tonillo J; Weber C; Gieseler H Mol Pharm; 2018 Jul; 15(7):2656-2664. PubMed ID: 29809017 [TBL] [Abstract][Full Text] [Related]
50. Platinum(II) as bifunctional linker in antibody-drug conjugate formation: coupling of a 4-nitrobenzo-2-oxa-1,3-diazole fluorophore to trastuzumab as a model. Waalboer DC; Muns JA; Sijbrandi NJ; Schasfoort RB; Haselberg R; Somsen GW; Houthoff HJ; van Dongen GA ChemMedChem; 2015 May; 10(5):797-803. PubMed ID: 25809281 [TBL] [Abstract][Full Text] [Related]
51. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Hodoniczky J; Zheng YZ; James DC Biotechnol Prog; 2005; 21(6):1644-52. PubMed ID: 16321047 [TBL] [Abstract][Full Text] [Related]
52. Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate. Kim MT; Chen Y; Marhoul J; Jacobson F Bioconjug Chem; 2014 Jul; 25(7):1223-32. PubMed ID: 24873191 [TBL] [Abstract][Full Text] [Related]
53. Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates. Jeffrey SC; Torgov MY; Andreyka JB; Boddington L; Cerveny CG; Denny WA; Gordon KA; Gustin D; Haugen J; Kline T; Nguyen MT; Senter PD J Med Chem; 2005 Mar; 48(5):1344-58. PubMed ID: 15743178 [TBL] [Abstract][Full Text] [Related]
55. In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab-MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios. Bryant P; Pabst M; Badescu G; Bird M; McDowell W; Jamieson E; Swierkosz J; Jurlewicz K; Tommasi R; Henseleit K; Sheng X; Camper N; Manin A; Kozakowska K; Peciak K; Laurine E; Grygorash R; Kyle A; Morris D; Parekh V; Abhilash A; Choi JW; Edwards J; Frigerio M; Baker MP; Godwin A Mol Pharm; 2015 Jun; 12(6):1872-9. PubMed ID: 25894424 [TBL] [Abstract][Full Text] [Related]
56. Statistics of the distribution of the abundance of molecules with various drug loads in maytansinoid antibody-drug conjugates. Goldmacher VS; Amphlett G; Wang L; Lazar AC Mol Pharm; 2015 Jun; 12(6):1738-44. PubMed ID: 25635630 [TBL] [Abstract][Full Text] [Related]
57. [Advances in the study of site-specific antibody-drug conjugates]. Sun Y; Huang R; Sun BW Yao Xue Xue Bao; 2015 Oct; 50(10):1225-31. PubMed ID: 26837166 [TBL] [Abstract][Full Text] [Related]
58. Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay. Lai KC; Deckert J; Setiady YY; Shah P; Wang L; Chari R; Lambert JM Pharm Res; 2015 Nov; 32(11):3593-603. PubMed ID: 25630819 [TBL] [Abstract][Full Text] [Related]
59. Chemical de-conjugation for investigating the stability of small molecule drugs in antibody-drug conjugates. Chen T; Su D; Gruenhagen J; Gu C; Li Y; Yehl P; Chetwyn NP; Medley CD J Pharm Biomed Anal; 2016 Jan; 117():304-10. PubMed ID: 26406314 [TBL] [Abstract][Full Text] [Related]